miRNA FOR TREATING CANCER AND FOR USE WITH ADOPTIVE IMMUNOTHERAPIES

Abstract

In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy.

1 - 32 . (canceled) 
     
     
         33 . A pharmaceutical preparation comprising miR-124, miR-142, or miR-138. 
     
     
         34 . The pharmaceutical preparation of  claim 33 , wherein the miRNA comprises a phosphoramidate linkage, a phosphorothioate linkage, a phosphorodithioate linkage, or an O-methylphosphoroamidite linkage. 
     
     
         35 . The pharmaceutical preparation of  claim 33 , wherein the miRNA is a LNA. 
     
     
         36 . The pharmaceutical preparation of  claim 33 , wherein the pharmaceutical preparation is formulated for intravenous, intraperitoneal, intratumoral, intrathecal, intranasal, intralymphatic, or oral administration. 
     
     
         37 . The pharmaceutical preparation of  claim 33 , wherein the miRNA is comprised in a liposome, nanoparticle, or exosome. 
     
     
         38 . The pharmaceutical preparation of  claim 33 , wherein the pharmaceutical preparation comprises N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP) or Lipofectamine™. 
     
     
         39 - 45 . (canceled) 
     
     
         46 . The pharmaceutical preparation of  claim 37 , wherein the miRNA is comprised in a nanoparticle. 
     
     
         47 . The pharmaceutical composition of  claim 38 , wherein the pharmaceutical preparation comprises Lipofectamine™. 
     
     
         48 . The pharmaceutical composition of  claim 36 , wherein the pharmaceutical preparation is formulated for intravenous administration. 
     
     
         49 . The composition of  claim 37 , wherein the miRNA is comprised in a liposome. 
     
     
         50 . The composition of  claim 49 , wherein the liposome comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), polyethylene glycol (PEG), or cholesterol.